A conotoxin mutant and its preparation method and application

By performing specific mutations on the amino acid sequence of conotoxin Mr1.1, a conotoxin mutant with stronger inhibitory activity was formed, which solved the problem of insufficient specificity and analgesic activity of α9α10 nAChR, and achieved high efficiency for α9α10 nAChR Inhibit and long-term analgesia, and reduce addictiveness.

CN115246872BInactive Publication Date: 2024-11-26OCEAN UNIV OF CHINA
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202110225081.5
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-04-27
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing α9α10 acetylcholine receptor inhibitors have insufficient specific and analgesic activity on α9α10 nAChR and have addictive problems.

Method used

By performing specific mutations on the amino acid sequence of conotoxin Mr1.1, a conotoxin mutant with stronger inhibitory activity is formed, including forming intrachain disulfide bonds with cysteine ​​at position 2 and 8 and The construction of intrachain disulfide bonds with the cysteine ​​at position 16 was constructed, and the mutant was prepared by Fmoc solid-phase polypeptide synthesis technology.

Benefits of technology

A stronger inhibitory activity and better analgesic activity on α9α10 nAChR were achieved, while reducing addictiveness, and the analgesic effect lasted for 24 hours.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115246872B_ABST
    Figure CN115246872B_ABST
Patent Text Reader

Abstract

The method discloses a conotoxin mutant, the amino acid sequence of the mutant is SEQ ID NO: 1GCCX1X2X3ACX4X5X6X7X8X9X 10 CX 11 ; wherein X1 is selected from S, T, A, R, Alg, Dap or Dab; ​​X2 is selected from H, R, W, A or N; X3 is selected from P or Hyp; X4 is selected from S, L, V, A, D, K, T, Dab, Dap or Y; X5 is selected from V, L, A, Y, R, Cit, Dap, Dab, D or K; X6 is selected from N, Q or A; X7 is selected from N, H or A; X8 is P or A; X9 is selected from D, E, S or A; X 10 I or A; X 11 The C-terminal is amidated, or is selected from Y, L or R. The invention also provides a preparation method and application. The conotoxin mutant provided by the invention has obvious analgesic effect and is non-addictive.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and relates to a series of conotoxin mutants having a strong inhibitory effect on α9α10 acetylcholine receptors, and a preparation method and application thereof. Background Art

[0002] Acetylcholine receptors are pentameric ion channel proteins located on the cell membrane and composed of different subunits. They can regulate synaptic transmission between neuromuscular junctions and the central and peripheral nervous systems. According to the different receptor subunits, they can be divided into neuronal acetylcholine receptors such as α9α10 acetylcholine receptors (α9α10 nAChR), α7 nAChR and α3β2 nAChR, and muscle acetylcholine receptors such as α1β1γδ. Abnormalities in the structure and function of acetylcholine receptors are closely related to a series of pathological and physiological processes, and α9α10 nAChR is a newly discovered target for the treatment of pain in recent years. Molecules that have an inhibitory effect on α9α10 nAChR have potential analgesic activity. In addition, α9α10 nAChR has been found to be overexpressed in tumor cells, and α9α10 nAChR is also considered a target for tumor drug research (Pharmacol Ther. 2020 Dec10; 222: 107792.). Conus snails that selectively target α9α10 nAChR also have the potential to be developed as anti-tumor drugs.

[0003] Conotoxin (CTX) is a small peptide toxin secreted by the carnivorous mollusk Conus living in tropical oceans. It is used to anesthetize prey. It is usually composed of 10-40 amino acids, short peptides rich in disulfide bonds, and has many pharmacological activities. It mainly targets membrane proteins, especially ion channel receptors, membrane receptors and transport proteins. According to their pharmacological activities and molecular targets, conotoxins can be divided into many different families such as α and μ. Among them, α-conotoxin (α-CTxs) can specifically act on acetylcholine receptors and exert an inhibitory effect. α-CTxs are usually short peptides composed of 12-19 amino acids containing two pairs of disulfide bonds, and their disulfide bonds are Cys Ⅰ -Cys Ⅲ , Cys Ⅱ -Cys ⅣMr1.1 is a new α-4 / 7 conotoxin obtained by PCR amplification of the cDNA sequence of the venom tube of Conus marmoreus. Can Peng.et.al.'s research showed that Mr1.1 can specifically act on mouse α7 nAChR in vitro and can inhibit the current intensity of α6α3β2 nAChR caused by acetylcholine by 40% at the 1μmol level. It also showed analgesic activity in in vivo experiments. Summary of the invention

[0004] The present invention found in the in-depth study of α-conotoxin that a specific mutation of the Mr1.1 amino acid residue can have specificity for α9α10 nAChR and show significant analgesic activity.

[0005] The technical problem described in the present invention can be solved by the following technical solutions:

[0006] A conotoxin mutant, the amino acid sequence of the mutant is SEQ ID NO: 1GCCX1X2X3ACX4X5X6X7X8X9X 10 CX 11 ;

[0007] wherein X1 is selected from any one of S, T, A, R, (S)-2-amino-3-guanidinopropionic acid (Alg), L-2,3-diaminopropionic acid (Dap) or L-2,4-diaminobutyric acid (Dab); X2 is selected from any one of H, R, W, A or N; X3 is selected from any one of P or Hyp; X4 is selected from any one of S, L, V, A, D, K, T, Dab, Dap or Y; X5 is selected from any one of V, L, A, Y, R, Cit, Dap, Dab, D or K; X6 is selected from any one of N, Q or A; X7 is selected from any one of N, H or A; X8 is P or A; X9 is selected from any one of D, E, S or A; X 10 I or A; X 11 The C-terminus is acylated, or any one of Y, L or R is selected.

[0008] In one embodiment according to the present invention, the amino acid sequence of the mutant is SEQ ID NO: 2GCCSHPACSVNNPDICX 11 ; Among them, X 11 Selected from any one of Y, L or R.

[0009] In one embodiment according to the present invention, the N-terminus of the mutant amino acid sequence is methylated or acetylated.

[0010] In one embodiment according to the present invention, the amino acid sequence of the mutant is SEQ ID NO: 3GCCSHPACSVNNPDIC* (* represents C-terminal amidation), or, SEQ ID NO: 4GCC(Dap)HPACSVNNPDIC* (* represents C-terminal amidation).

[0011] In one embodiment according to the present invention, it is characterized in that, in the mutant, the cysteines at positions 2 and 8 form an intrachain disulfide bond, and the cysteines at positions 3 and 16 form an intrachain disulfide bond.

[0012] The present invention further provides a method for preparing the above-mentioned conotoxin mutant, comprising:

[0013] 1) Activating the resin with dichloromethane and N,N-dimethylformamide, and then obtaining the linear peptide SEQ ID NO: 1 according to a solid phase synthesis method;

[0014] 2) using a mixed solution of trifluoroacetic acid, water, phenol and triisopropylsilane to cut the resin, removing the trifluoroacetic acid by rotary evaporation, and then adding icy ether to precipitate a white solid; dissolving the white solid with water to obtain a heavy solution by centrifugation, and then freeze-drying the heavy solution to obtain a solid powder;

[0015] 3) protecting the thiol groups of the cysteine ​​at positions 2 and 8 in the sequence SEQ ID NO:1 with a first thiol protecting group; protecting the cysteine ​​at positions 3 and 16 in the sequence SEQ ID NO:1 with a second thiol protecting group;

[0016] 4) constructing the disulfide bonds at positions 2 to 8 and at positions 3 to 16 respectively according to the disulfide bond construction methods for the first thiol protecting group and the second thiol protecting group.

[0017] In one embodiment of the present invention, when the resin is activated in step 1), the volume ratio of dichloromethane to N,N-dimethylformamide is 1:1.

[0018] In one embodiment of the present invention, in step 2), the volume ratio of trifluoroacetic acid, water, phenol and triisopropylsilane is 80:3-7:3-7:1-5.

[0019] In one embodiment according to the present invention, in step 3), the first thiol protecting group and the second thiol protecting group are trityl or acetamidomethyl, respectively, and the first thiol protecting group and the second thiol protecting group are different;

[0020] Preferably, when the first thiol protecting group or the second thiol protecting group is a trityl group, an air oxidation method is used to construct a disulfide bond; further preferably, the air oxidation method is achieved by a method comprising the following steps: dissolving a solid powder at a concentration of 0.2 mg / mL in a 0.2 M aqueous solution of ammonium bicarbonate, stirring the reaction at room temperature for 48 hours, and freeze-drying the mixture after the reaction;

[0021] When the first thiol protecting group or the second thiol protecting group is acetamidomethyl, the disulfide is constructed by a method comprising the following steps:

[0022] The reaction solvent is prepared by mixing water, acetonitrile and TFA in a volume ratio of 5:5:0.01, an appropriate amount of white solid powder is weighed and dissolved in the reaction solvent, and then 1-5 mg / mL iodine / acetonitrile solution is added, and the polypeptide concentration in the mixed solution is (1-3 mg / mL), and the mixture is mixed to make the solution colorless and clear, and lyophilized to obtain the product; more preferably, the iodine / acetonitrile solution is 2.5 mg / mL, and the ascorbic acid aqueous solution is 5 mg / mL.

[0023] The present invention further provides the use of the above-mentioned conotoxin mutant in the preparation of α9α10 nAChR inhibitors, the preparation of molecular probes or reagents for studying the structure and function of ion channel receptors, the preparation of drugs for treating neuralgia-related diseases, or the preparation of drugs or auxiliary agents for treating tumors. Preferably, the neuralgia-related diseases are selected from peripheral neuropathy or central pain; preferably, the peripheral neuropathy is selected from trigeminal neuralgia, sphenopalatine ganglion pain, pterygoid neuralgia, geniculate ganglion pain, greater occipital neuralgia, intercostal neuralgia, cervical-shoulder-arm neuralgia, brachial plexus neuritis, ulnar neuralgia, median neuralgia, lateral femoral cutaneous neuralgia, femoral neuralgia, sciatica, coccygeal pain, causalgia, herpes zoster, and cancer pain; the central pain is spinal cord pain, thalamic pain, pons, medullary pain, and cerebral cortical pain.

[0024] The beneficial effects of the present invention are:

[0025] Compared with α7 nAChR, the conotoxin mutant Mr1.1 provided by the present invention has stronger inhibitory activity on α9α10 nAChR and is a specific inhibitor of α9α10 nAChR. In further research, the present invention discovered a Mr1.1 mutant with stronger inhibitory activity on α9α10nAChR, and through in vivo experiments on Mr1.1[S4Dap], it was found that it has good analgesic activity and no obvious addictiveness. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1 The figure is a schematic diagram of the preparation process of conotoxin mutants in one embodiment of the present invention.

[0027] Figure 2 It is a schematic diagram of the inhibitory activity of Mr1.1 and the mutants provided by the present invention on human α9α10 nAChR (hα9α10 nAChR).

[0028] Figure 3 This is the test result of mechanical pain 1 hour after drug administration. The results show that the analgesic activity of Mr1.1 mutant (S4Dap) is much higher than that of morphine and RgIA4 (Proc Natl Acad Sci US A. 2017 Mar 7; 114(10): E1825-E1832.);

[0029] Figure 4 This is the test result spectrum of heat pain test 1 hour after drug administration. The results show that Mr1.1[S4Dap] has much higher analgesic activity than morphine and RgIA4;

[0030] Figure 5 This is the result of testing mechanical pain 24 hours after medication. The results show that the analgesic activity of Mr1.1[S4Dap] is far greater than that of RgIA4, and the analgesic time lasts for 24 hours;

[0031] Figure 6 This is the test result of heat pain 24 hours after medication. The results show that the analgesic activity of Mr1.1[S4Dap] is far greater than that of RgIA4, and the analgesic time lasts for 24 hours;

[0032] Figure 7 This is the result of the addiction evaluation (CPP test). The results show that Mr1.1[S4Dap] is the same as RgIA4 and is not addictive. However, morphine, as a positive control, has significant addictive properties.

[0033] Figure 8 It is a schematic diagram of the structure of some Mr1.1 mutants. DETAILED DESCRIPTION

[0034] The present invention will be further described in detail below in conjunction with specific embodiments, but the present invention is not limited to the scope of the embodiments.

[0035] Example 1 Peptide Synthesis

[0036] This experiment used Fmoc solid phase peptide synthesis technology, Rink MBHA resin, piperidine as Fmoc protecting group removal reagent, HCTU and DIPEA as coupling conditions.

[0037] Preparation method

[0038] The active polypeptide of the present invention can be a natural polypeptide (or wild-type polypeptide), a recombinant polypeptide or a synthetic polypeptide. The polypeptide of the present invention can be isolated, chemically synthesized, or recombinant. Accordingly, the polypeptide of the present invention can be produced by conventional separation and extraction methods, or can be artificially synthesized by conventional methods, or can be produced by recombinant methods. Preferably, the active polypeptide of the present invention can be synthesized by solid phase Fmoc chemistry.

[0039] For example, the active polypeptide Mr1.1[S4Dap] of the present invention can be expressed as follows Figure 1 The method synthesis of the process shown specifically includes the steps:

[0040] (1) Activating the resin with dichloromethane and N,N-dimethylformamide in a volume ratio of 1:1, and then obtaining a linear peptide represented by SEQ ID NO:4 GCC(Dap)HPACSVNNPDIC* (* represents C-terminal amidation) by a solid phase synthesis method;

[0041] (2) using a mixed solution of trifluoroacetic acid, water, phenol and triisopropylsilane to cut the resin, trifluoroacetic acid: water: phenol: triisopropylsilane = 88: 5: 5: 2 (V / V), removing the trifluoroacetic acid by rotary evaporation, adding icy ether, and precipitating a white solid. After centrifugation, the solid was dissolved in water and freeze-dried using a freeze dryer to obtain a solid powder;

[0042] (3) constructing two pairs of disulfide bonds, the sulfhydryl protecting groups selected for cysteine ​​at positions 2 and 8 are trityl, and the sulfhydryl protecting groups selected for cysteine ​​at positions 3 and 16 are acetamidomethyl;

[0043] Construct the disulfide bond at position 2 and position 8:

[0044] Using the air oxidation method, 50 mg of solid powder was taken and dissolved in 150 mL of 0.2 M ammonium bicarbonate aqueous solution at a concentration of 0.2 mg / mL. The mixture was placed in a 250 mL eggplant-shaped bottle with electromagnetic stirring and reacted at room temperature for 48 h. A white solid powder was obtained using a freeze dryer.

[0045] Construct the disulfide bonds at positions 3 and 16:

[0046] Weigh 10 mg of white solid powder and dissolve it in a reaction solvent, wherein water: acetonitrile: TFA = 5:5:0.01, V / V. Add 3 mL of iodine / acetonitrile solution to the reaction solvent to keep the solution yellow. The concentration of the iodine / acetonitrile solution is 5 mg / mL. Stir the reaction in a 50 mL eggplant-shaped bottle at room temperature for 30 minutes, then add a 5 mg / mL ascorbic acid aqueous solution and mix well to make the solution colorless and clear. After freeze-drying, the final product, a white solid powder, is obtained.

[0047] Figure 8Shown is a partial structural schematic diagram of conotoxin prepared according to the above steps.

[0048] Example 2 Electrophysiological activity test

[0049] The cRNA of human α9α10 acetylcholine receptor was prepared using an in vitro transcription kit, and its concentration was measured by the OD value under UV260m. African clawed frog oocytes were collected by dissection, and the cRNA of the two subunits was injected into the frog eggs on the first and second days, with an injection volume of 5ng each, and cultured in ND-96. 1-4 days after injection, the oocytes expressing α9α10 acetylcholine receptor were used for electrophysiological activity testing. The specific test method is: a clawed frog oocyte injected with cRNA is placed in a 30uL Sylgard recording tank with a diameter of 4mm and a depth of 2mm, and ND96 perfusion fluid (96.0mM NaC1, 2.0mM KC1, 1.8mM CaCl2 1.0mM MgCl2, 5mM HEPES, pH 7.1-7.5) containing 0.1mg / ml bovine serum albumin (BSA) is perfused by gravity. All conotoxin solutions also contained 0.1 mg / mL BSA to reduce nonspecific adsorption. A switching valve was used to switch between perfusion of toxin or acetylcholine. ACh-gated currents were recorded online with a two-electrode voltage clamp amplifier set at the "slow" position and clamp gain at the maximum (×2000) position. Glass electrodes were drawn from glass capillaries with an outer diameter of 1 mm and an inner diameter of 0.75 mm and filled with 3M KCl as voltage and current electrodes. The membrane voltage was clamped at -70 mV, and the entire system was controlled and recorded by a computer. ACh pulses were automatically perfused for 1 s every 5 min, and the concentration of ACh was 6 μM. The current responses of at least 6 oocytes were recorded for each peptide, and the current data tested were statistically analyzed using GraphPad Prism software.

[0050] The results are as follows Figure 2 The schematic diagram of the inhibitory activity of Vc1.1 (1μM), Mr1.1 and its mutants (100nM) on human α9α10 nAChR (hα9α10nAChR) is shown. (The whole-cell current of hα9α10 nAChR is activated by 6μM acetylcholine). It shows that S4Dap has the strongest hα9α10 nAChR inhibitory activity, and S4Dab, S9Dap, V10R, etc. also show higher inhibitory activity. In addition, S4A, S9A, S9G, P13O, I15L, I15Y, 17R, N-terminal methylated peptide, and N-terminal acetylated peptide basically retain the activity of wild Mr1.1. The combination of the above variants is expected to have better activity

[0051] Example 3 Characterization of analgesic activity in animals:

[0052] The analgesic activity test used the rat sciatic chronic compression injury (CCI) model. 24 rats weighing 120-150g were purchased from Jinan Pengyue Animal Breeding Center and divided into four groups for adaptive training. After one week of training, two of the groups were modeled. The modeling process was as follows: After the rats were anesthetized by intraperitoneal injection of 2% sodium pentobarbital, the hair of the right leg was removed, the skin of the right lower limb was cut 1-2cm under sterile conditions, the muscles and fascia were bluntly separated, the sciatic nerve trunk was exposed, and four knots were tied with 4-0 chrome catgut with a spacing of 1mm. The tightness was required to be until the rat toes twitched slightly, so as not to affect the blood supply of the epineurium. After the ligation was completed, 40,000 units of sodium penicillin were used to clean the wound, and finally sutured. After the operation, 40,000 units of sodium penicillin were injected into the affected limb muscle for three consecutive days to prevent infection. In the remaining two groups, one group was used as a blank control and the other group was used as a sham operation group. Only the sciatic nerve trunk was exposed without ligation and compression to simulate the effect of the wound on the pain threshold of rats. After one week, when the thresholds of the two groups of model rats dropped to the lowest value, they were given intramuscular injections for two consecutive weeks. One group was injected with normal saline every day, and the other group was given Mr1.1[S4Dap] at a dose of 1.6×10 -4 mg / mg. 24 h after daily administration, the mechanical pain threshold of rats was measured with an IITC electronic analgesic, and the thermal pain threshold of rats was measured with an IITC plantar hot spot analgesic. In the thermal pain test, the working light intensity was set to "025", the standby light intensity was set to "010", and the preset time was set to "20". The obtained data were statistically analyzed using GraphPad Prism software.

[0053] Figure 3 This is the test result of mechanical pain 1 hour after drug administration. The results show that Mr1.1[S4Dap] (Mr1.1 mutant in the figure) has much higher analgesic activity than morphine and RgIA4 (Proc Natl Acad Sci US A. 2017 Mar 7; 114(10): E1825-E1832.).

[0054] Figure 4 This is the test result spectrum of heat pain test 1 hour after drug administration. The results show that Mr1.1[S4Dap] (Mr1.1mutant in the figure) has much higher analgesic activity than morphine and RgIA4.

[0055] Figure 5 This is the result of testing mechanical pain 24 hours after drug administration. The results show that the analgesic activity of Mr1.1[S4Dap] (Mr1.1 mutant in the figure) is far greater than that of RgIA4, and the analgesic time lasts for 24 hours.

[0056] Figure 6 This is the test result graph of heat pain 24 hours after medication. The results show that the analgesic activity of Mr1.1[S4Dap] (Mr1.1mutant in the figure) is far greater than that of RgIA4, and the analgesic time lasts for 24 hours.

[0057] Example 4 Addiction Evaluation:

[0058] This study used the conditioned preference (CPP) experiment to evaluate the addiction of rats. The device used in the conditioned place preference experiment in this experiment was a three-box CPP system. The interior of the left box was all black, and the inside of the right box was black and white stripes with equal spacing. The two boxes were 30cm apart. The inside of the middle box was grayish white, 30cm in size, and 10cm in size. There was a shuttle door between the middle box and the left and right boxes, which was a circular arched hole between the 10cm boxes. The shuttle door can be controlled by manually moving the partition. When conducting a CPP experiment, it is necessary to ensure soft light and no noise around. The entire experiment is divided into three stages: pretreatment stage, training stage and testing stage:

[0059] Pretreatment stage: On the first day after the rats adapted to the environment, the partition of the CPP box was removed to open the shuttle door, and the rats entered from the middle box. The rats were allowed to freely shuttle between the three boxes for 15 minutes, and no data was recorded at this time. On the 2nd and 3rd days, the time the rats stayed in each box within 15 minutes was recorded, and the average of the experimental data of the two days was taken. Rats with no obvious preference were selected for subsequent experiments. In the subsequent experiments, the rats' non-preferred box was used as the companion drug box.

[0060] Training phase: The rats were divided into four groups, namely, the morphine administration group with a black box as a companion drug box, the morphine administration group with a black and white box as a companion drug box, the Mr1.1 mutant (i.e., Mr1.1[S4Dap]) administration group with a black box as a companion drug box, and the Gex-2 administration group with a black and white box as a companion drug box, with 6 rats in each group. At 9:30 a.m. on the 1st / 3rd / 4th / 7th day of the training phase and at 15:30 p.m. on the 2nd / 4th / 6th / 8th day, the morphine group and the Mr1.1 mutant group were injected intramuscularly with the corresponding drugs. During the training process, the dosage of morphine was gradually increased from 5 mg / kg to 10 mg / kg. The Mr1.1 mutant group was continuously injected with 1 nM, and the control group was injected with saline. The drug injection amount was 200 shots. After the drug injection, the rats were immediately placed in the companion drug box and allowed to move freely for 40 minutes. At 15:30 p.m. on days 1 / 3 / 4 / 7 and at 9:30 a.m. on days 2 / 4 / 6 / 8, the three groups were injected intramuscularly with an equal amount of normal saline and placed in a non-companion medicine box to allow the rats to move freely for 40 min.

[0061] Testing phase: On the first day after training, the rats' CPP scores were tested. The specific method was as follows: remove the partition of the CPP box to open the shuttle door, put the rats in the middle box, and let them shuttle freely between different boxes. The time the rats stayed in different boxes within 15 minutes was recorded, and the changes in the rats' preferences were observed. On the second day after training, each rat was injected with 0.01 mg / kg naloxone to induce the withdrawal reaction. The rats were then put in the middle box to let them shuttle freely between different boxes. The time the rats stayed in different boxes within 15 minutes was recorded, and the changes in the rats' preferences were observed. During the test, the experimenters followed the double-blind principle.

[0062] Figure 7 This is the result of the addiction evaluation (CPP test), which shows that Mr1.1 mutant (i.e. Mr1.1[S4Dap]) is not addictive like RgIA4. However, morphine as a positive control showed obvious addiction.

[0063] The above embodiments are only used to illustrate the present invention, and are not intended to limit the patent of the present invention. It should be pointed out that a person skilled in the art can make various changes and modifications without departing from the scope of the present invention, and these all belong to the protection scope of the present invention. Therefore, all equivalent changes and modifications made to the scope of the claims of the present invention should belong to the coverage of the claims of the present invention. Sequence Listing <110> Ocean University of China <120> A conotoxin mutant and its preparation method and application <160> 16 <170> SIPOSequenceListing 1.0 <210> 1 <211> 17 <212> PRT <213> Artificial Sequence <220> <221> VARIANT <222> (4) <223> S, T, A, R, Alg, Dap or Dab <220> <221> VARIANT <222> (5) <223> Selected from H, R, W, A or N <220> <221> VARIANT <222> (6) <223> P or Hyp <220> <221> VARIANT <222> (9)..(9) <223> S, L, V, A, D, K, T, Dab, Dap or Y <220> <221> VARIANT <222> (10)..(10) <223> V, L, A, Y, R, Cit, Dap, Dab, D, or K <220> <221> VARIANT <222> (11)..(11) <223> Select from N, Q or A <220> <221> VARIANT <222> (12)..(12) <223> N, H or A <220> <221> VARIANT <222> (13) <223> P or A <220> <221> VARIANT <222> (14)..(14) <223> Select from D, E, S or A <220> <221> VARIANT <222> (15) <223> I or A <220> <221> VARIANT <222> (17) <223> Selected from Y, L or R, or C-terminal amidation <220> <221> DISULFID <222> (2)..(8) <223> Cysteine ​​forms intrachain disulfide bonds <220> <221> DISULFIDE <222> (3)..(16) <223> Cysteine forms an intramolecular disulfide bond <220> <221> UNSURE <222> (4)..(4) <223> The 'Xaa' at position 4 represents Ser, Thr, Ala, Arg, Alg, Dap or Dab. <220> <221> UNSURE <222> (5)..(5) <223> The 'Xaa' at position 5 represents His, Arg, Trp, Ala or Asn. <220> <221> UNSURE <222> (6)..(6) <223> The 'Xaa' at position 6 represents Pro or Hyp. <220> <221> UNSURE <222> (9)..(9) <223> The 'Xaa' at position 9 represents Ser, Leu, Val, Ala, Asp, Lys, Thr, Dab, Dap or Tyr. <220> <221> UNSURE <222> (10)..(10) <223> The 'Xaa' at position 10 represents Val, Leu, Ala, Tyr, Arg, Cit, Dap, Dab, Asp or Lys. <220> <221> UNSURE <222> (11)..(11) <223> The 'Xaa' at location 11 stands for Asn, Gln or Ala. <220> <221> UNSURE <222> (12)..(12) <223> The 'Xaa' at location 12 stands for Asn, His or Ala. <220> <221> UNSURE <222> (13)..(13) <223> The 'Xaa' at location 13 stands for Pro or Ala. <220> <221> UNSURE <222> (14)..(14) <223> The 'Xaa' at location 14 stands for Asp, Glu,Ser or Ala. <220> <221> UNSURE <222> (15)..(15) <223> The 'Xaa' at location 15 stands for Ile or Ala. <220> <221> UNSURE <222> (17)..(17) <223> The 'Xaa' at location 17 stands for Tyr, Leu, Arg oramidation. <220> <221> UNSURE <222> (4)..(4) <223> The 'Xaa' at location 4 stands for Gln, Arg, Pro, or Leu. <220> <221> UNSURE <222> (5)..(5) <223> The 'Xaa' at location 5 stands for Gln, Arg, Pro, or Leu. <220> <221> UNSURE <222> (6)..(6) <223> The 'Xaa' at location 6 stands for Gln, Arg, Pro, or Leu. <220> <221> UNSURE <222> (9)..(9) <223> The 'Xaa' at location 9 stands for Gln, Arg, Pro, or Leu. <220> <221> UNSURE <222> (10)..(10) <223> The 'Xaa' at location 10 stands for Gln, Arg, Pro, or Leu. <220> <221> UNSURE <222> (11)..(11) <223> The 'Xaa' at location 11 stands for Gln, Arg, Pro, or Leu. <220> <221> UNSURE <222> (12)..(12) <223> The 'Xaa' at location 12 stands for Gln, Arg, Pro, or Leu. <220> <221> UNSURE <222> (13)..(13) <223> The 'Xaa' at location 13 stands for Gln, Arg, Pro, or Leu. <220> <221> UNSURE <222> (14)..(14) <223> The 'Xaa' at location 14 stands for Gln, Arg, Pro, or Leu. <220> <221> UNSURE <222> (15)..(15) <223> The 'Xaa' at location 15 stands for Gln, Arg, Pro, or Leu. <220> <221> UNSURE <222> (17)..(17) <223> The 'Xaa' at location 17 stands for Gln, Arg, Pro, or Leu. <400> 1 Gly Cys Cys Xaa Xaa Xaa Ala Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys 1 5 10 15 Xaa <210> 2 <211> 17 <212> PRT <213> Artificial Sequence <220> <221> VARIANT <222> (17)..(17) <223> Selected from Y, L, or R <220> <221> UNSURE <222> (17)..(17) <223> The 'Xaa' at location 17 stands for Tyr, Leu, or Arg. <220> <221> UNSURE <222> (17)..(17) <223> The 'Xaa' at location 17 stands for Gln, Arg, Pro, or Leu. <400> 2 Gly Cys Cys Ser His Pro Ala Cys Ser Val Asn Asn Pro Asp Ile Cys 1 5 10 15 XA <210> 3 <211> 16 <212> PRT <213> Artificial Sequence <220> <221> AMIDATION <222> (16) <223> Amidation <400> 3 Gly Cys Cys Ser His Pro Ala Cys Ser Val Asn Asn Pro Asp Ile Cys 1 5 10 15 <210> 4 <211> 16 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (4) <223> X = 4-diaminosuccinic acid (Dap) <220> <221> UNSURE <222> (4) <223> The 'Xaa' at location 4 stands for Dap. <220> <221> UNSURE <222> (4) <223> The 'Xaa' at location 4 stands for Gln, Arg, Pro, or Leu. <400> 4 Gly Cys Cys Xaa His Pro Ala Cys Ser Val Asn Asn Pro Asp Ile Cys 1 5 10 15 <210> 5 <211> 16 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (4) <223> X = diaminosuccinic acid (Dap) <220> <221> AMIDATION <222> (16) <223> Amidation <220> <221> UNSURE <222> (4) <223> The 'Xaa' at location 4 stands for Dap. <220> <221> UNSURE <222> (4) <223> The 'Xaa' at location 4 stands for Gln, Arg, Pro, or Leu. <400> 5 Gly Cys Cys Xaa His Pro Ala Cys Ser Val Asn Asn Pro Asp Ile Cys 1 5 10 15 <210> 6 <211> 16 <212> PRT <213> Artificial Sequence <220> <221> MUTAGEN <222> (9)..(9) <223> X = diaminosuccinic acid (Dap) <220> <221> AMIDATION <222> (16) <223> Amidation <220> <221> UNSURE <222> (9)..(9) <223> The 'Xaa' at location 9 stands for Dap. <220> <221> UNSURE <222> (9)..(9) <223> The 'Xaa' at location 9 stands for Gln, Arg, Pro, or Leu. <400> 6 Gly Cys Cys Ser His Pro Ala Cys Xaa Val Asn Asn Pro Asp Ile Cys 1 5 10 15 <210> 7 <211> 16 <212> PRT <213> Artificial Sequence <220> <221> AMIDATION <222> (16) <223> Amidation <400> 7 Gly Cys Cys Ser His Pro Ala Cys Ser Arg Asn Asn Pro Asp Ile Cys 1 5 10 15 <210> 8 <211> 16 <212> PRT <213> Artificial Sequence <220> <221> AMIDATION <222> (16) <223> Amidation <400> 8 Gly Cys Cys Ala His Pro Ala Cys Ser Val Asn Asn Pro Asp Ile Cys 1 5 10 15 <210> 9 <211> 16 <212> PRT <213> Artificial Sequence <220> <221> AMIDATION <222> (16) <223> Amidation <400> 9 Gly Cys Cys Ser His Pro Ala Cys Ala Val Asn Asn Pro Asp Ile Cys 1 5 10 15 <210> 10 <211> 16 <212> PRT <213> Artificial Sequence <220> <221> AMIDATION <222> (16) <223> Amidation <400> 10 Gly Cys Cys Ser His Pro Ala Cys Gly Val Asn Asn Pro Asp Ile Cys 1 5 10 15 <210> 11 <211> 16 <212> PRT <213> Artificial Sequence <220> <221> AMIDATION <222> (16) <223> Amidation <400> 11 Gly Cys Cys Ser His Pro Ala Cys Ser Val Asn Asn Ala Asp Ile Cys 1 5 10 15 <210> 12 <211> 16 <212> PRT <213> Artificial Sequence <220> <221> AMIDATION <222> (16) <223> Amidation <400> 12 Gly Cys Cys Ser His Pro Ala Cys Ser Val Asn Asn Pro Asp Leu Cys 1 5 10 15 <210> 13 <211> 16 <212> PRT <213> Artificial Sequence <220> <221> AMIDATION <222> (16) <223> Amidation <400> 13 Gly Cys Cys Ser His Pro Ala Cys Ser Val Asn Asn Pro Asp Tyr Cys 1 5 10 15 <210> 14 <211> 17 <212> PRT <213> Artificial Sequence <400> 14 Gly Cys Cys Ser His Pro Ala Cys Ser Val Asn Asn Pro Asp Ile Cys 1 5 10 15 Arg <210> 15 <211> 16 <212> PRT <213> Artificial Sequence <220> <221> FORMYLATION <222> (1) <223> N-terminal methylation <220> <221> AMIDATION <222> (16) <223> C-terminal amidation <400> 15 Gly Cys Cys Ser His Pro Ala Cys Ser Val Asn Asn Pro Asp Tyr Cys 1 5 10 15 <210> 16 <211> 16 <212> PRT <213> Artificial Sequence <220> <221> ACETYLATION <222> (1) <223> N-terminal acetylation <400> 16 Gly Cys Cys Ser His Pro Ala Cys Ser Val Asn Asn Pro Asp Tyr Cys 1 5 10 15

Claims

1. A conotoxin mutant, It is characterized in that The amino acid sequence of the mutant is SEQ ID NO:4 GCC (Dap) HPACVSNNPDIC, and the C-terminus is amidated, wherein (Dap) refers to L-2,3-diaminopropionic acid; in the mutant, the cysteines at positions 2 and 8 form an intrachain disulfide bond, and the cysteines at positions 3 and 16 form an intrachain disulfide bond.

2. The method for preparing the conotoxin mutant according to claim 1, It is characterized in that include: 1) Activating the resin with dichloromethane and N,N-dimethylformamide, and then obtaining the linear peptide SEQ ID NO: 1 according to the solid phase synthesis method; 2) using a mixed solution of trifluoroacetic acid, water, phenol and triisopropylsilane to cut the resin, removing the trifluoroacetic acid by rotary evaporation, and then adding icy ether to precipitate a white solid; dissolving the white solid in water to obtain a heavy solution by centrifugation, and then freeze-drying the heavy solution to obtain a solid powder; 3) protecting the thiol groups of cysteine ​​at positions 2 and 8 in the sequence SEQ ID NO:1 with a first thiol protecting group; protecting the cysteine ​​at positions 3 and 16 in the sequence SEQ ID NO:1 with a second thiol protecting group; 4) constructing disulfide bonds at positions 3 to 16 and at positions 2 to 8 respectively according to the disulfide bond construction methods for the first thiol protecting group and the second thiol protecting group.

3. The preparation method according to claim 2, It is characterized in that When the resin is activated in step 1), the volume ratio of dichloromethane to N,N-dimethylformamide is 1:

1.

4. The preparation method according to claim 2, It is characterized in that In step 2), the volume ratio of trifluoroacetic acid, water, phenol and triisopropylsilane is 80:3-7:3-7:1-5.

5. The preparation method according to claim 2, It is characterized in that In step 3), the first thiol protecting group and the second thiol protecting group are trityl or acetamidomethyl, respectively, and the first thiol protecting group and the second thiol protecting group are different.

6. The preparation method according to claim 2, It is characterized in that In step 3), when the first thiol protecting group or the second thiol protecting group is a trityl group, an air oxidation method is used to construct a disulfide bond; When the first thiol protecting group or the second thiol protecting group is acetamidomethyl, the disulfide is constructed by a method comprising the following steps: The reaction solvent was prepared by mixing water, acetonitrile and TFA in a volume ratio of 5:5:0.01, and an appropriate amount of white solid powder was weighed and dissolved in the reaction solvent. Then, 1-5 mg / mL iodine / acetonitrile solution was added, and the peptide concentration in the mixed solution was 1-3 mg / mL. After stirring at room temperature for 30 minutes, an appropriate amount of ascorbic acid aqueous solution was added and mixed until the solution was colorless and clear, and then lyophilized.

7. The preparation method according to claim 6, It is characterized in that The air oxidation method is achieved by a method comprising the following steps: dissolving the solid powder in a 0.2 M aqueous solution of ammonium bicarbonate at a concentration of 0.2 mg / mL, stirring the reaction at room temperature for 48 hours, and freeze-drying the solid powder after the reaction.

8. The preparation method according to claim 6, It is characterized in that The iodine / acetonitrile solution was 5 mg / mL, and the ascorbic acid aqueous solution was 5 mg / mL.

9. Use of the conotoxin mutant according to claim 1 in the preparation of α9α10 nAChR inhibitors, the preparation of molecular probes or reagents for studying the structure and function of ion channel receptors, the preparation of drugs for treating diseases related to neuralgia, or the preparation of drugs or auxiliary agents for treating tumors.

10. The use according to claim 9, It is characterized in that The neuropathic pain-related disease is selected from peripheral neuropathic pain or central pain.

11. The use according to claim 10, It is characterized in that The peripheral neuropathy pain is selected from trigeminal neuralgia, sphenopalatine ganglion pain, pterygoid neuralgia, geniculate ganglion pain, occipital neuralgia, intercostal neuralgia, cervical and shoulder-arm neuralgia, brachial plexus neuritis, ulnar neuralgia, median neuralgia, lateral femoral cutaneous neuralgia, femoral neuralgia, sciatica, coccygeal pain, causalgia, herpes zoster, and cancer pain; the central pain is spinal cord pain, thalamic pain, pons, medulla oblongata pain, and cerebral cortex pain.

Citation Information

Cited By

  • Polypeptide with plasma stability and preparation method thereof

    CN117683088A